CliffBio

Daiichi Sankyo

Patent cliffs & loss of exclusivity

Daiichi Sankyo is an innovative global healthcare company that discovers, develops and delivers new standards of care.

Company

Company Operating StatusActive
Email format{first}.{last}
Facebook URLhttps://www.facebook.com/daiichisankyous
Legal Entity Identifier353800XGIU2IHQGC9504
LinkedIn URLhttps://www.linkedin.com/company/daiichi-sankyo
Pitchbook URLhttps://pitchbook.com/profiles/company/51036-40
Seedtable URLhttps://seedtable.com/companies/daiichi-sankyo
Twitter URLhttps://twitter.com/daiichisankyous

9 upcoming patent cliffs

DrugIngredientTypeCliff
  1. SAVAYSAEDOXABAN TOSYLATESmall mol.Mar 2028
  2. SAVAYSAEDOXABAN TOSYLATESmall mol.Mar 2028
  3. SAVAYSAEDOXABAN TOSYLATESmall mol.Mar 2028
  4. Enhertufam-trastuzumab deruxtecan-nxkiBiologicDec 2031
  5. VANFLYTAQUIZARTINIB DIHYDROCHLORIDESmall mol.Sep 2033
  6. VANFLYTAQUIZARTINIB DIHYDROCHLORIDESmall mol.Sep 2033
  7. Datrowaydatopotamab deruxtecan-dlnkBiologicJan 2037
  8. TURALIOPEXIDARTINIB HYDROCHLORIDESmall mol.Jul 2038
  9. TURALIOPEXIDARTINIB HYDROCHLORIDESmall mol.Jul 2038

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.